Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ropivacaine ER by PainReform for Post-Operative Pain: Likelihood of Approval
Ropivacaine ER is under clinical development by PainReform and currently in Phase III for Post-Operative Pain. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of PainReform's Ropivacaine ER?
Ropivacaine ER is a small molecule commercialized by PainReform, with a leading Phase III program in Post-Operative Pain. According to...
Risk adjusted net present value: What is the current valuation of PainReform's Ropivacaine ER?
Ropivacaine ER is a small molecule commercialized by PainReform, with a leading Phase III program in Post-Operative Pain. According to...